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DockingAbstract Human immunodeﬁciency virus integrase (HIV-1IN) is an emerging and potential drug
target for anti-HIV therapy. It is an enzyme essential for 30 processing and integration step in the
life cycle of HIV. In the present study a series of coumarin derivatives (containing 26 compounds) as
HIV-1IN inhibitors was subjected to quantitative structure–activity relationship (QSAR) analysis.
For building the regression models two different variable selection approaches namely, genetic
function approximation (GFA) and sequential multiple linear regression (SQ-MLR) were used
and compared to predict the HIV-1IN inhibition activity. Based on prediction, the best validation
model for 30 processing inhibition activity with squared correlation coefﬁcient (r2) = 0.8965, cross
validated correlation coefﬁcient (Q2) = 0.8307 and external prediction ability pred_r2 = 0.5400
showed that Henry’s law Constant (HLC), Partition Coefﬁcient (PC) and Dipole moment-Z com-
ponent (D3) were the positive contributors, whereas for integration inhibition activity, parameters
r2 = 0.8904, Q2 = 0.8174 and pred_r2 = 0.7159 showed HLC, Logarithm of Partition Coefﬁcient
(LogP) and Dipole moment-Y component (D2) contributed positively to the activity. The binding
mode pattern of the compounds to the binding site of integrase enzyme was conﬁrmed by docking
studies. The results of the present study may be useful for designing more potent HIV-1IN inhib-
itors.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Acquired immunodeﬁciency syndrome caused by HIV leads to
life-threatening opportunistic infections, malignancies, func-
tional impairment of the immune system and subsequently de-
stroys the body’s ability to ﬁght against infections (Kanazawa
and Matija Peterlin, 2001). Since ﬁrst reported in 1981 (Gott-
lieb et al., 1981), it has spread rapidly through the human pop-
ulation and became one of the most devastating diseases faced
by mankind. According to Joint United Nations Programme
on HIV/AIDS, an estimated 34 million people were living with
HIV worldwide at the end of 2010 (UNAIDS, 2011).
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are Reverse Transcriptase (RT) and Protease (PT) Inhibitors.
Rapid development of resistance to these inhibitors and toxicity
are the major problems associated with the current therapy
(Erickson and Burt, 1996). Therefore, the development of new
anti-HIV agents with varied structure and mechanism of action
is being focused. HIV-1IN is a very attractive and unexplored
target to develop new anti-HIV drugs as it plays a vital role in
replication cycle, has no cellular counterpart (Goldgur et al.,
1999) and only one FDA (Food and Drug Administration) ap-
proved drug raltegravir is being used in clinical practice (Summa
et al., 2008). Several reports have appeared on HIV-1IN inhib-
itory potency of variety of compounds. Examples of these com-
pounds include lignanolides (Eich et al., 1996), curcumins
(Mazumder et al., 1995), aurintricarboxylic acids (Cushman
and Sherman, 1992), dicaffeoyl quinic acids and analogues
(Robinson et al., 1996a,b), diaryl sulfones (Mazumder et al.,
1996) and G-rich oligonucleotides (Hansch, 1969). These inhib-
itors may be described in general as consisting of two aryl units,
at least one of which contains the 1,2-dihydroxy (catechol) pat-
tern, separated by an appropriate linker. The utility of the cate-
chol-containing inhibitors is signiﬁcantly diminished by
cytotoxicity due to in situ oxidation of the catechol moiety to
reactive quinone species (Kostova et al., 2006). In an attempt
to develop new inhibitors Zhao et al., synthesized a series of cou-
marin derivatives which do not contain catechol functionality
but possess good HIV-1IN inhibition activity.
TheQSARapproach helps to correlate the biological activity
of a series of compounds with the calculated molecular proper-
ties in terms of descriptors (Hansch et al., 2001). It saves re-
sources as well as speeds up the process of development of
new molecules. Several QSAR Studies have been performed
by other authors, which provide valuable insights in design
and development of HIV-1IN inhibitors (Yuan and Parrill,
2002;Cheng et al., 2010;Kaushik et al., 2011). As a part of ongo-
ing effort the present work is aimed to derive some statistically
signiﬁcant QSAR models for coumarin derivatives to correlate
anti-HIV-1IN activity to its physicochemical properties. Dock-
ing study is also performed to a newly identiﬁed pocket right be-
hind catalytic core domain (CCD) helix 4 (Rhodes et al., 2011) in
the IN enzyme to understand the binding mode pattern of the
compounds. The results obtained may contribute to further de-
sign and development of novel antiretroviral agents.
2. Materials and methods
2.1. Dataset
A dataset of coumarin derivatives containing 26 compounds
with well deﬁned activity (Zhao et al., 1997), was selected for
QSAR study. The compounds which do not have well deﬁned
activity were excluded from dataset. The biological activity
data in the form of IC50 (molar concentration of the drug lead-
ing to 50% inhibition of enzyme Integrase) value in lm (micro-
moles) were converted into negative logarithmic dose in moles
(pIC50) for QSAR Analysis (Table 1).
2.2. Molecular modeling and generation of molecular descriptors
The molecular modeling study was performed using CS Chem-
Ofﬁce version 8.0 software (Mendelsohn, 2004). Structure ofall the compounds was drawn using ChemDraw Ultra module
of the program and transferred to Chem3DUltra module to create
the three-dimensional (3D) structure. These structures were then
subjected to energy minimization using molecular mechanics
(MM2) server until the root-mean square (RMS) gradient value
became smaller than 0.1 kcal/mol A˚. Energy minimized molecules
were subjected to reoptimization via Austin model-1 (AM1) meth-
od using the restricted closed-shell wave function of the molecular
orbital package (MOPAC) module until the RMS gradient at-
tained a value of 0.0001 kcal/mol A˚. The geometry optimization
of the lowest energy structure was carried out using EF (Eigenvec-
tor Following) routine. Most stable structure for each compound
was generated and used for calculating various physicochemical
parameters like thermodynamic, steric and electronic descrip-
tors (Table S1 in Supplementary material).
2.3. Variable selection and model generation
Although many molecular descriptors are available, only a
subset of them is statistically signiﬁcant in terms of correlation
with biological activity. Thus, it is very important to address
the variable selection method for deriving the optimal QSAR
model. GFA (Rogers and Hopﬁnger, 1994) and SQ-MLR ap-
proaches were adopted to select the best possible variables as
well as for the generation of QSAR models.
2.3.1. GFA method
GFA algorithm is a search method to ﬁnd exact or approximate
solutions to optimization and search problems. GFA is conceived
from (1) genetic algorithm and (2) Friedman’s multivariate adap-
tive regression splines (MARS) algorithm. The following steps
were performed: (1) initial population of equations were generated
by randomnumber of descriptors, (2) pairs from the population of
equations were chosen at random, crossovers were performed and
progeny equations were generated, (3) the ﬁtness of each progeny
equationwas assessed by lack of ﬁt (LOF) score that automatically
penalizes models with too many features. A distinctive feature of
GFA is that it generates a population of equations rather than a
single equation as do most other statistical methods. The range
of variations in this population gives added information on the
quality of ﬁt and importance of the descriptors. The ﬁtness func-
tion, i.e., lack-of-ﬁt is calculated by
LOF ¼ LSE
1 Cþdp
M
 2
where c is the number of basis functions, d is the smoothing
parameter, M is the number of samples in the training set,
LSE is the least square error and p is the total number of fea-
tures contained in all basis functions. Selected descriptors are
given in supplementary material (Table S2).
2.3.2. SQ-MLR
In order to establish a correlation between physicochemical
parameters as independent variables and pIC50 as dependent
variable employing sequential multiple linear regression analy-
sis method, dataset was transferred to the statistical program
VALSTAT (Gupta et al., 2004). In sequential multiple regres-
sion, the program searches all the permutations and combina-
tions sequentially for the data set. The ± data within the
parentheses are the standard deviation, associated with the
Table 1 Structure and biological activity of coumarin derivatives.
O
OH
O
O O
HOR
S. no. R IC50 (lM) pIC50 (M)
30 Processing Integration 30 Processing Integration
1 43.4 38.8 4.3665 4.4111
2 OH 128 74 3.8927 4.1307
3
OH
OCH3 177 76 3.7520 4.1191
4
N
CH3
CH3 88 50 4.0550 4.3010
5 NO2 50 12 4.3010 4.9208
6 O
OH
48 49 4.3187 4.3098
7 S 100 148 4.0000 3.8297
8 O 34 112 4.4685 3.9507
9
N
29 14 4.5376 4.8538
10 19 9.0 4.7212 5.0457
11 14 13 4.8538 4.886
12 10 7.8 5.0000 5.1079
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Table 1 (continued)
S. no. R IC50 (lM) pIC50 (M)
30 Processing Integration 30 Processing Integration
13 5.5 3.7 5.2596 5.4317
14
O
8.5 14 5.0705 4.8538
15
O O
8.0 3.7 5.0969 5.4317
16
O OO O
OH HO
1.5 0.8 5.6989 6.0969
O OH
HOR
OHO
OH
OO
S. no. R IC50 (lM) pIC50 (M)
30 Processing Integration 30 Processing Integration
17 H 46.3 44.9 4.3344 4.3477
18 17.2 22.2 4.7644 4.6536
19
O
OH
OH
O
OH
OH
O
O
0.37 0.33 6.4317 6.4814
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model was selected from the various statistically signiﬁcantequations on the basis of the r2, the standard error of estimate
(SEE), the sequential Fischer test (F), the bootstrapping
Table 1 (continued)
S. no. R IC50 (lM) pIC50 (M)
30 Processing Integration 30 Processing Integration
20 N 84 49 4.0757 4.3098
21 N 62 25 4.2076 4.6020
22 4.2 3.55 5.3767 5.4497
23 7.0 1.8 5.1549 5.7447
S. no. Compound IC50 (lM) pIC50 (M)
30 Processing Integration 30-Processing Integration
24 O
O
O
OH
OO 121 122 3.9172 3.9136
25 O
O
O
HO
OO
O
O
35.7 22.5 4.4473 4.6478
26 OO
OH
OH 300 325 3.5228 3.4881
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dard deviation (Sbs), q
2 using leave-one-out method, signiﬁ-
cance level (P) on the basis of chance statistics (evaluated as
the ratio of the equivalent regression equations to the total
number of randomized sets; a chance value of 0.001 corre-sponds to 0.1% chance of fortuitous correlation) and outliers
(on the basis of Z-score value).
Selection of training and test sets is one of the most impor-
tant steps in QSAR analysis. There must be sufﬁcient struc-
tural diversity which could cover the complete range of
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Figure 1 Normal distribution curves of individual descriptors used in the best validation models.
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training set of 18 compounds (18, 19, 4, 17, 20, 6, 12, 22, 1, 13,
25, 16, 7, 11, 21, 26, 9, and 5) and test set of 8 compounds (10,
8, 2, 3, 23, 24, 14, and 15) by straightforward random selection
method (70:30 ratio) through activity sampling automatically
by VALSTAT. After selection of training set and test set com-
pounds, the dataset was further subjected to MLR analysis to
predict the HIV-1IN inhibition activity of test set compounds
using STATSTICA software (Statsoft, 2001). The descriptors
selected for model generation are given in supplementary
material (Table S2). The reliability of selected variables was
checked by their normal distribution behavior. The distribu-
tion curves of individual descriptors used in the best validation
models are given in Fig. 1.
2.4. Validation of QSAR models
The QSAR models were developed by GFA and SQ-MLR
methods and evaluated using the following statistical parame-
ters: n (the number of compounds in regression), correlation
coefﬁcient (r), r2, F, Kubinyi function (FIT), variance, SEE,
P, r2bs, and Sbs for statistical signiﬁcance. The F-test reﬂects
the ratio of the variance explained by the model and the vari-
ance due to the error in the regression. High values of the F-
test indicate that the model is statistically signiﬁcant. Kubinyi
function (FIT) is a closely related statistical parameter to F-
test. The greater the FIT value the better the linear equation.
The validation parameters calculated were Q2, standard devia-
tion of sum of square of difference between predicted and ob-
served values (SPRESS) and standard deviation of error of
prediction (SDEP). For reliability of the model, probable error
of correlation (PE) was also calculated. If the value of correla-tion coefﬁcient (r) is more than six times of PE then the expres-
sion is good and reliable (Kumar et al., 2011). Finally, the
derived QSAR models were used for the prediction of the bio-
logical activity of the compounds in the test set and pred_r2
was calculated for evaluating the prediction ability of the mod-
els. A QSAR model is predictive if the following conditions are
satisﬁed (Golbraikh and Tropsha, 2002a).
r2 > 0:6; q2 > 0:6 and pred r2 > 0:5:
Internal validation was carried out using ‘leave-one-out’
(q2, LOO) method (Cramer et al., 1988). The cross-validated
coefﬁcient (q2) was calculated using the following equation:
q2 ¼ 1
Pðyobs  ypredÞ2
ðP yobs  ymeanÞ2
where yobs and ypred are the observed and predicted activity of
the training set, respectively, and ymean is the average activity
of all molecules in the training set. However, a high q2 value
does not necessarily give a suitable representation of the real
predictive power of the model, so an external validation was
also carried out. The external predictive ability of the selected
models was calculated using the following equation:
pred r2 ¼ 1
Pðyi  y^iÞ2Pðyi  ymeanÞ2
where yi and yˆi are the observed and predicted activity of the
ith molecule in the test set, respectively, and ymean is the aver-
age activity of all molecules in the training set.
The robustness of QSAR models was also checked by Y-
randomization test. In this technique, the dependent variable
(biological activity) is randomly shufﬂed and a new QSAR
Figure 2 Structure of reference ligand.
QSAR and docking studies of coumarin derivatives as potent HIV-1 integrase inhibitors S1087model is developed using the original independent variable.
The new QSAR models (after several trials) are expected to
have low r2 and Q2 values, if the reverse happens then an
acceptable QSAR model cannot be obtained for the speciﬁc
modeling method and data. This technique ensures the robust-
ness of a QSAR model (Tropsha et al., 2003; Wold et al.,
2008).
The QSAR models developed using different statistical
tools can be applied to deﬁne its applicability domain for dif-
ferent datasets. For this purpose, an external data set of 50
compounds (Sharma et al., 2011) with well deﬁned HIV-1IN
inhibition activity was selected which was different from the
current series, and used as external test set for the prediction
of their HIV-1IN inhibition activity (Table S3 in Supplemen-
tary material).
2.5. Docking study
To date, no full strength structure of HIV-1IN is available to
elucidate the spatial arrangement of its three domains: N-ter-
minal (NTD), catalytic core (CCD) and C-terminal (CTD).
The relatively rapid emergence of resistance against raltegravir
necessitates sustained research not only on novel INSTIs (IN
strand transfer inhibitors) but also on entirely novel inhibitor
classes. In recent years signiﬁcant progress has been witnessed
in the area of the development of allosterically targeted IN
inhibitors. It presents an extremely advantageous approachFigure 3 (a) Superimposition of the reference ligand. (b) Superimposi
of HIV-1IN.for the discovery of compounds effective against IN
strand-transfer drug-resistant viral strains (Al-Mawsawi and
Neamati, 2011).
Docking was performed using GOLD software package
version 4.0 (Genetic Optimization for Ligand Docking) (Jones
et al., 1997). 3D co-crystallized structure of HIV-1IN was ta-
ken from the Research Collaboratory for Structural Bioinfor-
matics (RCSB) Protein Data Bank (PDB ID: 3NF7). 3NF7 is a
new site in integrase as a valid region for the structure-based
design of allosteric integrase inhibitors which has been identi-
ﬁed using a structure-based design process (Rhodes et al.,
2011). Structure of all the compounds was built and energy
minimized using Maestro module of Schrodinger Suit (Mae-
stro, 2009). Feasible and unique conformations for each com-
pound were generated over an energy range of 20 kcal/mol.
Processing of the protein was done by adding hydrogen atoms
to assign appropriate ionization states to both acidic and basic
amino acid residues and removing remaining water molecules
from protein. Binding site was deﬁned by studying the interac-
tion of reference ligand to the active residues in the cavity. The
key characteristic of a good docking program is its ability to
reproduce the experimental binding modes of ligands. To test
this, ligand [5-{(5-chloro-2-oxo-2, 3-dihydro-1H-indol-1- yl)
methyl}-1, 3-benzodioxole-4-carboxylic acid] was taken (as ref-
erence ligand) out of the X-ray structure of its protein–ligand
complex (3NF7) and docked back into its binding site (Fig. 2).
The docked binding mode was then compared with the
experimental binding mode, and a root-mean-square deviation
(RMSD) between the two was calculated. The prediction of a
binding mode is considered successful if the RMSD is below a
certain value usually 2.0 A˚ (Verdonk et al., 2003). The exact
superimposition was obtained with a RMSD value 0.4505
which conﬁrmed that prediction of the binding mode was suc-
cessful. Compounds from the dataset were docked in the pre-
viously deﬁned cavity and interaction points as well as
Goldscore ﬁtness was compared with the reference ligand. Ral-
tegravir was also included in the docking study to compare its
binding orientation in active site with the reference ligand and
compounds of the series. The redocked conformation of thetion and binding of reference ligand to active residues in the cavity
Figure 4 Scatter Plot between the observed and predicted
activity of training and test set (30 processing inhibition activity).
Table 2 Validation parameters of generated QSAR models.
Validation parameters r2bs Sbs PE P Q
2 Spress SDEP Pred_r
2 LOF
Model 2 0.8823 0.0965 0.0159 <0.001 0.5353 0.5297 0.4671 0.4981 0.2675
Model 4 0.9045 0.0793 0.0162 <0.001 0.8307 0.3184 0.2808 0.5400 0.2701
Model 6 0.9038 0.1024 0.0117 <0.001 0.8705 0.2784 0.2456 0.5262 0.3376
Model 8 0.9050 0.0742 0.0172 <0.001 0.8174 0.3576 0.3154 0.7159 0.3258
S1088 V.K. Srivastav, M. Tiwarireference ligand and binding to the active residues in the bind-
ing site are shown in Fig. 3.
3. Results and discussion
3.1. QSAR study
The model generated for 30 processing inhibition activity by
GFA algorithm was Model 1.
3.1.1. Model 1
Log(1/IC50) = [3.2733(±0.3430)] + PMIZ [8.2353(±2.5328)] +
NVDW [0.0161(±0.0327)] + TE [0.0248 (±0.0186)]
n= 26, r= 0.9046, r2 = 0.8066, Variance = 0.0804,
SEE = 0.2936, PE = 0.0213, F= 34.5544, FIT = 3.0089,
r2bs ¼ 0:8089, Sbs = 0.1257, P< 0.001, Q2 = 0.7076,
Spress = 0.3508, SDEP = 0.3243 LOF= 0.3392.
Validation was performed by dividing dataset into training
set and test set. The best model generated for 30 processing
inhibition activity using GFA method was Model 2.
3.1.2. Model 2
Log(1/IC50) = [3.3853(±0.3483)] + PMIZ [7.7998 (±2.4799)] +
SE [0.0092(±0.0254)] + TE [0.0259(±0.0170)]
n= 18, r= 0.9478, r2 = 0.8983, Variance = 0.0613,
SEE = 0.2477, PE = 0.0159, F= 39.2407, FIT = 4.0823,
r2bs ¼ 0:8823, Sbs = 0.0965, P= 0.001, Q2 = 0.5353,
Spress = 0.5297, SDEP = 0.4671
SQ-MLR analysis resulted in several signiﬁcant models
with respect to inhibition of 30 processing and integration
activity, respectively. Model 3 was selected for 30 processing
inhibition activity.
3.1.3. Model 3
Log(1/IC50) = [2.4610(±0.5291)] + HLC [0.0524(±0.0194)] +
PC [0.2376(±0.0698)] + D3 [0.0410(±0.0561)]
n= 26, r= 0.9095, r2 = 0.8273, Variance = 0.0856,
SEE = 0.2926, PE = 0.0225, F= 35.1433, FIT = 3.0122,
r2bs ¼ 0:8048, Sbs = 0.1158, P< 0.001, Q2 = 0.7569,
Spress = 0.3472, SDEP = 0.3193, LOF = 0.4072.
The best Validation model for 30 processing inhibition
activity was Model 4.
3.1.4. Model 4
Log(1/IC50) = [2.4937(±0.5187)] + HLC
[0.0516(±0.0190)] + PC [0.2456(±0.0733)] + D3
[0.0392(±0.0268)]
n=18, r=0.9468, r2 = 0.8965, Variance = 0.0620,
SEE= 0.2489, F=40.4276, FIT= 4.4919, r2bs ¼ 0:9045, Sbs =
0.0793, P=0.001, Q2 = 0.8307, Spress = 0.3184, SDEP = 0.2808.
Based on the statistical signiﬁcance and validation parame-
ters a comparison was done between the validation models(Model 2 and Model 4 for 30 processing activity) generated
by GFA and MLR methods (Table 2).
Model 2 showed lower Q2 and pred r2 values than Model 4
which meaned that prediction ability of Model 4 was much
better. Bootstrapping analysis was performed to access the
robustness and statistical conﬁdence. Higher value of r2bs and
lower value of Sbs, Spress and SDEP of Model 4 in comparison
to Model 2 revealed that Model 4 was robust and promising.
In the developed Model the value of coefﬁcient of correlation
was signiﬁcantly higher than the value of PE (0.097) support-
ing reliability and goodness. Based on the above results Model
4 was considered as the best validation model for 30 processing
inhibition activity. The accuracy of the Model 4 was ascer-
tained by correlation coefﬁcient (r= 0.9468), statistical signif-
icance more than 99% (against tabulated value F= 40.4276)
and low standard deviation (0.2489). The model shows that
thermodynamic parameter (HLC and PC) and electronic
parameter (D3) showed positive contribution. The correlation
matrix between the physicochemical parameters and the bio-
logical activity is presented in Table S4 (supplementary mate-
rial). HLC is a quantitative expression of the compound’s
partitioning nature between two phases. It is evident from
Table S2 that most potent compound of the series has the
highest value for HLC= 44.4244 and least active compound
has the lowest value for HLC= 11.0686. PC can be calculated
using an atom based approach and represents the hydropho-
bicity of the compounds. The positive contribution of PC con-
ﬁrmed the hydrophobic binding site of integrase protein and
suggested that substitution with lipophilic groups favors anti-
HIV-1IN activity. The measurement of dipole moment helps
in distinguishing between polar and non-polar molecules, as
it encodes information about the charge distribution in mole-
cules. It is particularly important in modeling solvation
properties of compounds which depend on solute/solvent
interactions and in fact are frequently used to represent the
dipolarity/polarizability term in linear solvation energy rela-
tionships. Moreover, it can be used to model the polar interac-
tions which contribute to the determination of the lipophilicity
Figure 5 Scatter plot between the observed and predicted
activity of training and test set (Integration inhibition activity).
QSAR and docking studies of coumarin derivatives as potent HIV-1 integrase inhibitors S1089of compounds (Todeschini and Consonni, 2008). Non-polar
molecules have zero dipole moment while polar molecules have
some value of dipole moment. The dipole moment of com-
pound nos. 16 and 19 was zero because the groups on either
side of linker were same. The robustness of the model was jus-
tiﬁed by the magnitude of bootstrapping r2 (0.8982), which was
near to the conventional r2 (0.8965). The internal validation
parameter of the model (q2 = 0.8307) was also good. The scat-
ter plot of observed activity versus predicted activity is shown
in Fig. 4.
The model selected for integration inhibition activity by
GFA was Model 5.
3.1.5. Model 5
Log(1/IC50) = [3.1965(±0.4617)] + PMIZ [8.9258 (±2.9132)] +
ce:hsp sp="0.25"/>NVDW [0.0195(±0.0170)] + TE
[3.0810(±7.4373)].
n= 26, r= 0.9217, r2 = 0.8496, Variance = 0.0745,
SEE = 0.2731, PE = 0.0196, F= 41.4302, FIT = 3.5511,
r2bs ¼ 0:8402, Sbs = 0.1084, P< 0.001, Q2 = 0.8169,
Spress = 0.3013, SDEP = 0.2771, LOF = 0.3063.
The best validation model resulted by dividing test set and
training set using GFA method was Model 6.
3.1.6. Model 6
Log(1/IC50) = [3.2314(±0.3253)] + PMIZ [8.1759(±2.2220)] +
VDWE [0.0231(±0.0156)] + TC [0.0362(±0.0558)].
n= 18, r= 0.9618, r2 = 0.9251, Variance = 0.0448,
SEE = 0.2117, PE = 0.0117, F= 35.6723, FIT = 6.408,Table 3 Observed, calculated and predicted activity (30 processing
S. no. Obs.a Obs.b Model 3 Mo
Cal. Pred. Ca
1 4.3665 4.4111 4.2241 4.2096 4.2
2 3.8927 4.1307 4.4084 4.4358 4.3
3 3.7520 4.1191 4.3117 4.3756 4.4
4 4.0555 4.3010 4.3799 4.4235 4.5
5 4.3010 4.9208 4.0406 3.9319 4.5
6 4.3187 4.3098 4.5089 4.5169 4.5
7 4.0000 3.8297 4.2954 4.3192 4.3
8 4.4685 3.9507 4.1810 4.1528 4.2
9 4.5376 4.8538 4.4140 4.4034 4.4
10 4.7212 5.0457 4.5436 4.5207 4.7
11 4.8538 4.8860 4.7228 4.7022 4.8
12 5.0000 5.1079 4.9356 4.9250 4.9
13 5.2596 5.4317 5.1638 5.1340 5.2
14 5.0705 4.8538 4.8816 4.8622 4.7
15 5.0969 5.4317 5.4911 5.6154 5.6
16 5.6989 6.0969 5.8067 5.8337 6.0
17 4.3344 4.3477 4.1659 4.1426 4.2
18 4.7644 4.6536 4.5773 4.5540 4.7
19 6.4317 6.4814 6.2277 5.9569 6.5
20 4.0757 4.3098 4.3718 4.4485 4.4
21 4.2076 4.6020 4.3077 4.3302 4.4
22 5.3767 5.4497 4.9213 4.8672 5.0
23 5.1549 5.7447 5.1118 5.1054 5.7
24 3.9172 3.9136 4.1741 4.2001 4.4
25 4.4473 4.6478 4.1010 4.0751 4.5
26 3.5228 3.4881 3.3570 3.2834 3.1
aObs.
bObs are the observed activity against 30 processing and integration, re
* Represents the test set compounds.r2bs ¼ 0:9058, Sbs = 0.1024, P< 0.001, Q2 = 0.8705, Spress =
0.2784, SDEP = 0.2456.
The model selected for integration inhibition activity by
MLR was Model 4.
3.1.7. Model 7
Log(1/IC50) = [2.1070(±0.4586)] + HLC
[0.0637(±0.0169)] + PC [0.2675(±0.0655)] + D2
[0.0409(±0.0321)]
n= 26, r= 0.9349, r2 = 0.8740, Variance = 0.0742,
SEE = 0.2724, F= 50.9052, FIT = 4.3633, PE = 0.0164,
P< 0.001, Q2 = 0.8346, Spress = 0.3122, SDEP = 0.2871.
LOF = 0.3767.and integration inhibition) of Coumarin derivatives.
de7 Model 4 Model 8
l. Pred. Cal. Pred. Cal. Pred.
761 4.2620 4.2919 4.2809 4.2471 4.2224
617 4.3823 * 4.4620 4.4261 4.4572
045 4.4308 * 4.3687 4.4809 4.5176
091 4.5252 4.4483 4.5253 4.5455 4.5738
946 4.5304 4.1121 3.9925 * 4.5800
152 4.5318 4.5668 4.5818 4.4603 4.4762
618 4.3952 4.3540 4.3969 * 4.3781
358 4.2569 * 4.2355 3.9566 3.9574
987 4.4701 4.4775 4.4700 4.5593 4.5272
478 4.7249 * 4.6207 * 4.7033
451 4.8393 4.8053 4.7928 * 4.8327
861 4.9729 5.0102 5.0133 4.9669 4.9237
185 5.1829 5.2426 5.2320 * 5.1335
813 4.7670 * 4.9553 4.8257 4.8142
125 5.6562 * 5.5760 * 5.6414
151 5.9956 5.8769 5.9412 5.8797 5.8079
639 4.2523 4.2042 4.1826 4.1886 4.1513
185 4.7248 4.6203 4.5996 * 4.7988
570 6.6562 6.2760 6.0007 6.4959 6.5186
319 4.4594 4.4007 4.4974 4.6496 4.7175
521 4.4183 4.3394 4.3751 4.5585 4.5469
553 5.0289 4.9725 4.9122 5.1408 5.0990
785 5.7953 * 5.1837 * 5.7845
200 4.5109 * 4.2401 4.3597 4.5454
395 4.5003 4.1607 4.1305 4.5157 4.3725
369 3.0015 3.3921 3.3128 3.1171 2.8922
spectively.
Table 4 Predicted activity and Goldscore ﬁtness of external data set.
S. no. 30 Processing activity (pIC50) Integration activity (pIC50) Goldscore ﬁtness
Obs. Pred. Residual Obs. Pred. Residual
1 4.1249 4.5308 0.4058 4.6020 4.4224 0.1796 56.8326
2 4.2839 4.6846 0.4006 4.8538 4.4916 0.3622 56.3636
3 4.1307 4.5332 0.4024 4.4948 4.3735 0.1213 54.8883
4 4.3467 4.6592 0.3124 5.0457 4.4632 0.5824 54.0343
5 4.0915 4.6671 0.5756 4.9208 4.4269 0.4938 56.3896
6 4.9586 4.7129 0.2456 5.3010 4.5242 0.7767 54.7906
7 4.1611 4.7895 0.6283 4.4559 4.6995 0.2436 60.4016
8 4.5528 4.8112 0.2583 5.1549 4.6482 0.5066 58.3345
9 4.2365 4.7957 0.5591 4.7212 4.6787 0.0425 54.1915
10 4.2076 4.5245 0.3169 4.4685 4.4130 0.0554 59.1822
11 4.0705 4.0705 4.3814 0.3108 4.2924 4.2728 0.0196
12 4.3279 4.9320 0.6041 4.7447 4.7248 0.0199 55.0176
13 4.2839 4.6509 0.3669 4.7958 4.7449 0.0509 53.9539
14 4.5686 4.7695 0.2009 4.8538 4.6177 0.2361 56.3071
15 4.6989 4.9911 0.2921 4.8860 4.7968 0.0892 60.0161
16 4.6382 5.0155 0.3773 5.4317 4.8281 0.6036 61.5000
17 4.0705 4.6188 0.5482 4.2757 4.3225 0.0468 57.7221
19 4.0000 4.7439 0.7439 4.0362 4.5724 0.5362 53.5698
20 4.1249 4.8786 0.7536 4.6020 4.6166 0.0145 59.8230
21 4.2596 4.9494 0.6898 4.7695 4.6887 0.0808 54.2735
22 4.1135 4.9639 0.8504 4.5228 4.7208 0.1979 60.1604
23 4.0604 4.7615 0.7011 4.3872 4.5059 0.1187 56.5870
24 4.4436 4.4703 0.0266 4.7695 4.2005 0.5690 55.4558
25 4.2839 4.6406 0.3566 4.6197 4.4169 0.2028 53.0649
26 4.2596 4.5983 0.3386 4.5228 4.4506 0.0722 52.9971
27 4.3010 4.6502 0.3492 4.5376 4.4848 0.0527 55.4299
28 4.4814 4.7957 0.3142 4.8239 4.5665 0.2573 56.6054
29 4.0861 4.8312 0.7450 4.4089 4.5937 0.1848 52.0521
33 4.6777 5.0294 0.3516 5.0457 5.1204 0.0747 67.2311
34 4.6020 5.2405 0.6384 4.7447 5.1334 0.3887 67.2029
35 4.6575 5.2437 0.5861 4.7958 5.1445 0.3486 76.7754
36 4.5228 4.4318 0.0910 4.7447 4.2283 0.5164 56.6828
37 4.0000 4.9108 0.9108 4.2596 4.5060 0.2463 63.1383
38 4.0362 4.8867 0.8505 4.3372 4.8040 0.4668 59.8100
39 4.2676 4.8141 0.5465 4.2676 4.5032 0.2356 61.4062
40 4.6382 4.6846 0.0463 4.9586 4.4979 0.4606 60.8004
42 4.1023 4.7720 0.6697 4.2006 4.4861 0.2854 58.8186
44 4.3098 4.1725 0.1373 4.4948 3.8466 0.6482 56.9085
45 4.7212 4.7043 0.0168 4.7447 4.5646 0.1800 57.0653
46 4.1487 4.4963 0.3476 4.2291 4.3251 0.0959 52.7239
50 4.4436 4.5294 0.0857 4.6777 4.1895 0.4882 53.0475
S1090 V.K. Srivastav, M. TiwariModel 8 was the validation model for integration inhibition
activity.
3.1.8. Model 8
Log(1/IC50) = [2.1032(±0.5361)] +HLC [0.0726(±0.0190)] +
LogP [0.3047(±0.1135)] + D2 [0.0346(±0.0257)]
n= 18, r= 0.9436, r2 = 0.8904, Variance = 0.0767,
SEE = 0.2770, F= 37.9443, FIT = 4.2160, r2bs ¼ 0:905,
Sbs = 0.0742, P< 0.001, Q
2 = 0.8174, Spress = 0.3576,
SDEP = 0.3154.
From Table 2 it is evident that Model 6 showed better value
for Q2 (0.8705) than Model 8 (0.8174) but a lower value for r2bs.
A high value of Q2 alone is an insufﬁcient criterion for a
QSAR model to be highly predictive (Golbraikh and Tropsha,
2002b). Based on prediction ability, Model 8 was selected as
the best validation model for integration inhibition activity.
Model 8 shows a good correlation between descriptors(HLC, LogP and D2) and integration inhibition activity.
The correlation matrix between the physicochemical parame-
ters and the biological activity is given in Table S5 (supplemen-
tary material). Correlation coefﬁcient (r= 0.9436), squared
correlation coefﬁcient (r2 = 0.8904), Low standard deviation
value (0.2770) of the model and a statistical signiﬁcance more
than 99% (F value = 37.9443) demonstrate the accuracy of
the model. Positive contribution of HLC, LogP and D2 indi-
cated favorable hydrophobic interactions that were responsible
for the enhancement of HIV-1IN inhibition activity. LogP is
one criterion used in medicinal chemistry to assess the drug-
likeness of a given molecule and used to calculate lipophilicity,
a function of potency and LogP that evaluate the quality of
designed compounds (Leeson and Springthorpe, 2007; Ed-
wards and Price, 2010). The scatter plot between calculated
and predicted activities of the training set and test set com-
pounds is given in Fig. 5.
Figure 6 A. Docked pose of compound no.19 in Binding site of 3NF7 [(green dots=Arene–Arene and H-Bond interaction), B. H-Bond
Interaction of compound no.19 (green dots=H-bond, red=oxygen, grey=carbon, blue=nitrogen) to His183 (green) and Lys188 (yellow)
in the binding site. C. Interaction of the Raltegravir (green dots=H-bond, red=oxygen, grey=carbon, blue=nitrogen) with the active
residues [His183 (yellow) and Lys188 (yellow)] of integrase binding site.
QSAR and docking studies of coumarin derivatives as potent HIV-1 integrase inhibitors S1091To conﬁrm the robustness of the derived best validation
models, a y-randomization test was performed by scrambling
the experimental activity at 1000 random numbers of trial con-
sidering the same number and deﬁnition of descriptors. The re-
sults so obtained show that original model was not obtained
due to a chance correlation. (Table S6 in Supplementary mate-
rial). All the regression models were checked for the presence
of outliers using Z-score method. There were no outliers pres-
ent in any model. Low value for LOF for all the models sug-
gested that selected models for both activities were robust.
The predicted biological activities of training and test set mol-
ecules are given in Table 3.
From Table 3, it is evident that the predicted activities of all
compounds in the training set and test set are in good agree-
ment with their corresponding experimental activities. As the
number of aromatic rings increases, the resonance energy per
p electron decreases. As a result, larger polynuclear aromatic
hydrocarbons have a tendency to undergo addition reaction
to an internal ring to give more stable compounds. Compound
nos. 16 and 19 in series have a large, highly complex but sym-metrical structure consisting of a coumarin dimer containing
the aryl substituent on the central linker methylene. As the
two of the original four coumarin units were removed from
compound 19, reduction in the potency resulted (compound
no. 18). Further if one more coumarin unit was removed from
compound 18 along with the linker, signiﬁcant reduction of
potency resulted (compound no. 26). Replacement of the cen-
tral phenyl ring by more extended aromatic system having
higher lipophilicity resulted in the enhancement of potency.
Presence of nitrogen in compound nos. 9, 20 and 21 reduces
the aromaticity, has low value for LogP and PC and thus
showed low biological activity. Dipole was also contributing
positively to the activity to a small extent suggesting that the
moiety, which increases the charge distribution over the mole-
cules, is favorable for the activity. For better understanding
the effect of dipole moment, DDE was also calculated which
shows that potent compounds in the series (compound nos.
16 and 19) have higher DDE value (25.8412 and 23.4976,
respectively) and least active compound (compound no. 26)
has the least DDE value (1.3283). The results of the present
Table 5 Speciﬁc H-Bond interactions between coumarin derivatives and amino acids.
S. no. Compound number H-Bond interaction
1 3, 5, 6, Arg199
2 17, 18, 20, 21 and 22 Leu158
3 24 Met154
4 22 Lys188
5 7 and 8 Val150
6 26 Arg199, Lys186, Lys188 and Ala196
S1092 V.K. Srivastav, M. Tiwaristudy conﬁrm that suitable aromatic substitution with high
lipophilicity is essential for HIV-1IN inhibition activity. QSAR
study by other authors (Bansal et al., 2007; Kaushik et al.,
2011) also resulted that lipophilicity is an important parameter
for HIV-1IN inhibition activity. Further, the selected models
were used to predict the HIV-1IN inhibition activity of exter-
nal dataset. Pred r2 and residual values were calculated for
both activities. The prediction attained from validation models
was in agreement with experimental activity (residual values
<0.7767) (Table 4).
3.2. Docking interpretation
The docked conformations showed that all ligands bind to the
active residues in the predeﬁned hydrophobic binding pocket.
The location of the docked ligands agreed well with that of
the docked reference ligand. The key residues in the binding
pocket were His183, Met154, Gly82, Glu157, Leu158, Ile151,
Val150, Val77 and Ile84. The reference ligand formed hydro-
gen bonding (H-bond) with His183 and Lys188 in the bindingTable 6 Goldscore ﬁtness value of the coumarin derivatives.
S. no. Goldscore ﬁtness
1 60.5947
2 59.9817
3 58.7115
4 63.2896
5 60.4170
6 59.2247
7 58.8453
8 59.3408
9 73.3419
10 61.2063
11 74.8875
12 61.6435
13 76.5358
14 58.1679
15 62.6386
16 72.1476
17 60.8233
18 60.3536
19 66.3396
20 59.7796
21 62.7426
22 60.6169
23 75.4920
24 61.9995
25 59.7655
26 35.5097
Reference ligand 67.8933
Raltegravir 53.3109site. His183 further binds with Gly82 through H-bond. Most
of compounds in the series showed H-bond interaction with
His183 which conﬁrmed that they interact with the integrase
enzyme like the reference ligand. In case of docked poses of
Raltegravir, H-bonds with His 183 and Lys188 were formed
which further conﬁrmed that these residues were important
for the HIV-1IN inhibition activity. Compound nos. 16 and
19, the most potent compound of the series showed a Gold-
score ﬁtness value of 72.1476 and 66.3396, respectively (Fig. 6).
Few compounds have Goldscore ﬁtness more than potent
compounds. This indicated that the compounds studied may
differ in the exact relationship between structure and inhibi-
tion, through interactions with different subsets of amino acids
in the binding pocket other than the active residues and
through the presence of non-overlapping binding pockets.
Interaction study is also important along with Goldscore ﬁt-
ness to validate the activity of compounds. The docked refer-
ence ligand was found to have H-Bond interaction between
an oxygen atom (O23) of the ligand and NH group of
His183, O19 of ligand and NH2 group of Lys188. Moreover,
a p-cation and p–p interaction was also found in the docked
conformation. His183 forms a p–p, and hydrophobic interac-
tion with most of the compounds of the series. Compound
no. 19 forms a p-cation interaction with Lys188 and a p–p
interaction with His183. In order to explain the binding of
these compounds, the H-bonding interactions with the other
surrounding residues in the hydrophobic binding pocket were
also investigated. Speciﬁc H-bond interactions between cou-
marin derivatives and amino acids are given in Table 5.
Strong H-bond interactions between the hydroxyl group of
Compound 16 and an oxygen atom of Gly82 and Lys188 were
formed. H-bond interactions between amino acids were also
found in the binding pocket (His183:Gly82, His183:Ala179,
Ile161:Glu157, Leu158:Met154, Lys188:Lys186, Arg199:-
Ser195, Arg199:Ser81, Lys186:Glu157 and Met154:Ile151).
The Goldscore ﬁtness of the compounds is given in Table 6.
The external data set compounds also showed good Gold-
score ﬁtness (Table 4) and formed H-bond interaction with
the active residues (His183 and Lys188) in the binding site.
Studies on mutational effect of residues of HIV-1IN showed
that mutations of His183, Lys188, and phenylalanine 185
had minor effects on the capacity of the mutated IN (Leavitt
et al., 1996; Berthoux et al., 2007). From the docking studies
it can be concluded that His183, Gly82, and Lys188, are the
key residues of the integrase binding site. Raltegravir also
interacts with these residues which further conﬁrmed that
binding to these residues is important for good anti HIV-
1IN activity. The docking results agreed well with the observed
biological activity data, which showed that the HIV-1IN inhi-
bition activity of the series conforms to the docking results.
QSAR and docking studies of coumarin derivatives as potent HIV-1 integrase inhibitors S10934. Conclusion
The present study showed that two coumarin units attached
via an aryl linker were important for HIV-1IN inhibition
activity. Removal of one coumarin unit resulted in lowering
of activity (compound no. 26). Through the iterative compu-
tational approach, it is possible to extract a simple and
highly informative model, having a high degree of predict-
ability for activity of coumarin derivatives against HIV-
1IN. The generated QSAR models were very informative
as they showed statistical signiﬁcance more than 99% and
good prediction ability. Further from the prediction ability
of external dataset it is conﬁrmed that the present QSAR
study holds true for different sets of compounds. The results
of this study suggested that substitution at the linker with
substituted aromatic rings having good lipophilic character-
istic was favorable for activity. Partition coefﬁcient contrib-
uted positively for both activities, responsible for the
hydrophobicity of the molecules. HLC, PC, LogP, and D
(dipole moment) were found to be the important parameters
for the HIV-1IN inhibition activity. The result of docking
study revealed that compounds showed interaction with
the active residues (His183, Lys188) in the binding site like
the reference ligand. Goldscore ﬁtness of the potent com-
pounds (16 and 19) was comparable with the reference as
well as with raltegravir. It can also be concluded that inter-
action study is a very important factor along with Goldscore
ﬁtness to understand the binding mode pattern of any com-
pound in the binding site. Further from this study it is evi-
dent that 3NF7 can be used as a good model for rational
drug design of HIV-1IN inhibitors.Acknowledgements
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